Marie Ménard
Revolution Medicines (United States)(US)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Cancer Research and Treatments, ATP Synthase and ATPases Research, Mechanisms of cancer metastasis, Pancreatic and Hepatic Oncology Research
Most-Cited Works
- → Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication(2022)245 cited
- → Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers(2024)241 cited
- → Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer(2024)157 cited
- → Bax targets mitochondria by distinct mechanisms before or during apoptotic cell death: a requirement for VDAC2 or Bak for efficient Bax apoptotic function(2014)128 cited
- → Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane(2014)122 cited
- → Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling(2018)92 cited
- → Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers(2023)61 cited
- → The Dependence Receptor TrkC Triggers Mitochondria-Dependent Apoptosis upon Cobra-1 Recruitment(2013)26 cited
- → T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma(2025)26 cited
- → Abstract 3475: RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models(2023)21 cited